Last updated: March 8, 2026
What is NDC 00904-7314?
NDC 00904-7314 corresponds to Voretigene Neparvovec (Luxturna), developed by Spark Therapeutics. It is an adeno-associated virus (AAV2) gene therapy approved by the FDA in December 2017 for inherited retinal disease caused by RPE65 gene mutations. It is marketed under the brand name Luxturna.
Market Size and Patient Population
Population of Eligible Patients
- Estimated US population with RPE65 mutation-related retinal dystrophy: 1,000 – 2,000 patients (source: FDA approval documents, orphan disease data).
- Global estimates: Approximately 6,000 patients, reflecting higher prevalence in certain populations and underdiagnosis (source: genetic epidemiology studies).
Diagnosis and Treatment Rates
- Diagnosis rate: Estimated at 50-70%, due to rarity and specialized testing requirements.
- Treatment uptake: Limited by high costs and accessibility, with approximately 500–1,000 patients receiving treatment in the US to date.
Market Drivers
- Orphan Drug Status: Approved for a rare disease, providing market exclusivity until at least 2027.
- Efficacy Data: Demonstrates significant visual improvement, encouraging further adoption.
- Pricing Strategy: Luxturna’s list price is $425,000 per eye, combining a total treatment cost of $850,000 for both eyes.
- reimbursement landscape: Payer coverage has been expanding, with many private insurers and government programs providing reimbursement.
Price and Revenue Projections
Current Price Point
- List price per eye: $425,000.
- Total treatment cost (both eyes): ~$850,000.
- Pricing considerations: Reflects high R&D costs, small patient population, and unmet medical needs.
Revenue Estimates (2023-2028)
| Year |
Patients Treated |
Gross Revenue (USD) |
Revenue Growth |
Comments |
| 2023 |
1,000 |
850 million |
0% |
Baseline based on current uptake |
| 2024 |
1,200 |
1.02 billion |
20% |
Increased diagnosis, coverage expansion |
| 2025 |
1,400 |
1.19 billion |
16.7% |
Broader treatment access |
| 2026 |
1,600 |
1.36 billion |
14.9% |
Market maturation |
| 2027 |
1,800 |
1.53 billion |
12.5% |
Pre-exclusivity expiration impact |
| 2028 |
2,000 |
1.70 billion |
11.1% |
Steady growth, potential price pressure |
Price Adjustments & Market Dynamics
- Pricing could decline by 10-20% within five years due to biosimilar competition or market saturation.
- Potential for volume growth if diagnosis rates improve with increased awareness and testing.
Competition and Market Outlook
- Biosimilar and Gene Therapy Competition: No direct biosimilar currently. Other gene therapies targeting different inherited retinal dystrophies are under development.
- Pipeline: Multiple pipelines for gene therapies targeting retinal diseases, but Luxturna remains the single approved product specific to RPE65 mutation.
- Market potential: Limited expansion due to the small patient pool; however, increased diagnosis could stabilize revenues.
Pricing Policy & Reimbursement Landscape
- Pricing policy: Set at $425,000 per eye, aligned with rare disease pricing frameworks.
- Reimbursement: Mostly covered by private insurers and Medicaid, with some coverage restrictions due to cost.
- Cost-effectiveness: Studies suggest Luxturna is cost-effective relative to lifetime care costs for untreated cases, but high upfront costs remain a barrier.
Regulatory and Policy Considerations
- Orphan Drug Designation: Ensures market exclusivity until 2027, after which biosimilar competition may emerge.
- Potential for label expansion: Trials are ongoing for related indications, which could create additional revenue streams.
- Pricing pressures: Proposals for value-based pricing and government cost controls may influence future pricing.
Key Market Risks
- Limited patient population constrains revenue potential.
- High treatment cost may restrict access, affecting sales.
- Entry of competing therapies could pressure pricing.
Key Takeaways
- Luxturna is a high-cost, low-volume therapy with a current global revenue potential approaching $2 billion annually, assuming steady market penetration.
- Revenue growth depends on diagnosis rates, reimbursement success, and market saturation.
- Price sustainability faces risks from biosimilars, market expansion challenges, and policy shifts toward cost containment.
FAQs
Q1: What factors influence the pricing of Luxturna?
Pricing reflects R&D costs, small patient population, regulatory exclusivity, and the value assigned to visual improvement. Reimbursement negotiations and market competition can lead to price adjustments.
Q2: How many patients are eligible for Luxturna worldwide?
Approximately 6,000 patients globally, with the US accounting for about 1,000–2,000 cases.
Q3: What are the key growth limitations for Luxturna?
Limited patient pool, high upfront costs, diagnosis underpenetration, and potential regulatory or reimbursement changes.
Q4: Are biosimilar competitors imminent?
No direct biosimilar competitors are approved yet. However, pipeline development in gene therapy could introduce competition in 5–10 years.
Q5: How does treatment reimbursement impact market penetration?
Coverage variability influences patient access; broader insurance acceptance correlates with increased treatment volumes and revenue.
References
[1] Food and Drug Administration (FDA). (2017). Approval Letter for Luxturna.
[2] Spark Therapeutics. (2022). Luxturna Prescribing Information.
[3] Genetic and Rare Diseases Information Center. (2021). Inherited Retinal Dystrophies.
[4] IQVIA. (2022). Global Gene Therapy Market Reports.
[5] Institute for Clinical and Economic Review (ICER). (2020). Cost-effectiveness analysis of Luxturna.
